[Comparative analysis of bone complications/manifestations in sporadic and MEN1-related primary hyperparathyroidism].

S V Pylina, A K Eremkina, A R Elfimova, A M Gorbacheva, N G Mokrysheva
{"title":"[Comparative analysis of bone complications/manifestations in sporadic and MEN1-related primary hyperparathyroidism].","authors":"S V Pylina, A K Eremkina, A R Elfimova, A M Gorbacheva, N G Mokrysheva","doi":"10.14341/probl13385","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Multiple endocrine neoplasia type 1 (MEN1) - is a rare syndrome with an autosomal dominant inheritance pattern caused by a mutation in the tumor suppressor gene (MEN1). Parathyroid involvement is the most common MEN1 manifestation resulting in primary hyperparathyroidism (mPHPT). Data on the prevalence and structure of bone disease in mPHPT compared to sporadic one (sPHPT) are often incomplete and contradictory.</p><p><strong>Aim: </strong>The purpose of this study was to compare the severity of bone involvement between mPHPT and sPHPT.</p><p><strong>Materials and methods: </strong>A single-center retrospective study was conducted among young patients in the active phase of PHPT and without prior parathyroidectomy in anamnesis. The analysis included the main parameters of calcium-phosphorus metabolism, bone remodeling markers, as well as an assessment of disease complications. Bone mineral density (BMD) was measured using dual-energy X-ray absorptiometry (DXA) at sites of lumbar spine, femur and radius. Trabecular bone score (TBS) was applied to estimate trabecular microarchitecture. All patients included in the study underwent genetic testing.</p><p><strong>Results: </strong>Group 1 (mPHPT) included 26 patients, and group 2 (sSHPT) included 30 age-matched patients: the median age in group 1 was 34.5 years [25; 39], in group 2 - 30.5 years [28; 36], (p=0.439, U-test). Within group 1, the subgroup 1A (n=21) was formed with patients without other hormone-produced neuroendocrine neoplasms (NEN) in the gastrointestinal tract (GI) and the anterior pituitary gland. The duration of PHPT was comparable in both groups: mPHPT - 1 year [0; 3] versus sPHPT - 1 year [0; 1], (p=0.533, U-test). There were no differences in the main parameters of calcium-phosphorus metabolism, as well as in the prevalence of kidney complications. In the mPHPT group, bone abnormalities were observed significantly more often compared to sPHPT: 54 vs 10% (p=&lt;0.001; F-test). Statistically significant differences were revealed both in BMD and in Z-score values of the femoral neck and total hip, which were lower in the mPHPT group. These differences remained significant when comparing subgroup 1A with sPHPT.</p><p><strong>Conclusion: </strong>MEN1-associated PHPT may be accompanied by a more severe decrease in BMD in the femoral neck and total hip compared to sPHPT regardless of the other hormone-producing NEN. Clarifying the role of mutation in the MEN1 gene in these processes requires further study.</p>","PeriodicalId":101419,"journal":{"name":"Problemy endokrinologii","volume":"70 1","pages":"81-90"},"PeriodicalIF":0.0000,"publicationDate":"2024-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10926251/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Problemy endokrinologii","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.14341/probl13385","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Multiple endocrine neoplasia type 1 (MEN1) - is a rare syndrome with an autosomal dominant inheritance pattern caused by a mutation in the tumor suppressor gene (MEN1). Parathyroid involvement is the most common MEN1 manifestation resulting in primary hyperparathyroidism (mPHPT). Data on the prevalence and structure of bone disease in mPHPT compared to sporadic one (sPHPT) are often incomplete and contradictory.

Aim: The purpose of this study was to compare the severity of bone involvement between mPHPT and sPHPT.

Materials and methods: A single-center retrospective study was conducted among young patients in the active phase of PHPT and without prior parathyroidectomy in anamnesis. The analysis included the main parameters of calcium-phosphorus metabolism, bone remodeling markers, as well as an assessment of disease complications. Bone mineral density (BMD) was measured using dual-energy X-ray absorptiometry (DXA) at sites of lumbar spine, femur and radius. Trabecular bone score (TBS) was applied to estimate trabecular microarchitecture. All patients included in the study underwent genetic testing.

Results: Group 1 (mPHPT) included 26 patients, and group 2 (sSHPT) included 30 age-matched patients: the median age in group 1 was 34.5 years [25; 39], in group 2 - 30.5 years [28; 36], (p=0.439, U-test). Within group 1, the subgroup 1A (n=21) was formed with patients without other hormone-produced neuroendocrine neoplasms (NEN) in the gastrointestinal tract (GI) and the anterior pituitary gland. The duration of PHPT was comparable in both groups: mPHPT - 1 year [0; 3] versus sPHPT - 1 year [0; 1], (p=0.533, U-test). There were no differences in the main parameters of calcium-phosphorus metabolism, as well as in the prevalence of kidney complications. In the mPHPT group, bone abnormalities were observed significantly more often compared to sPHPT: 54 vs 10% (p=<0.001; F-test). Statistically significant differences were revealed both in BMD and in Z-score values of the femoral neck and total hip, which were lower in the mPHPT group. These differences remained significant when comparing subgroup 1A with sPHPT.

Conclusion: MEN1-associated PHPT may be accompanied by a more severe decrease in BMD in the femoral neck and total hip compared to sPHPT regardless of the other hormone-producing NEN. Clarifying the role of mutation in the MEN1 gene in these processes requires further study.

[散发性和与MEN1相关的原发性甲状旁腺功能亢进症骨并发症/病变的比较分析]
背景:多发性内分泌瘤病1型(MEN1)是一种罕见的常染色体显性遗传综合征,由肿瘤抑制基因(MEN1)突变引起。甲状旁腺受累是 MEN1 最常见的表现,可导致原发性甲状旁腺功能亢进症(mPHPT)。与散发性甲状旁腺功能亢进症(sPHPT)相比,有关mPHPT骨病的发病率和结构的数据往往不完整且相互矛盾:在处于PHPT活动期的年轻患者中开展了一项单中心回顾性研究,这些患者在病史中没有进行过甲状旁腺切除术。分析包括钙磷代谢的主要参数、骨重塑指标以及疾病并发症评估。在腰椎、股骨和桡骨部位使用双能 X 射线吸收测定法(DXA)测量骨矿物质密度(BMD)。骨小梁评分(TBS)用于估算骨小梁微结构。所有参与研究的患者都接受了基因检测:第一组(mPHPT)包括 26 名患者,第二组(sSHPT)包括 30 名年龄匹配的患者:第一组的中位年龄为 34.5 岁 [25; 39],第二组为 30.5 岁 [28; 36],(P=0.439,U 检验)。在第 1 组中,第 1A 亚组(n=21)由胃肠道和垂体前叶没有其他激素分泌性神经内分泌肿瘤(NEN)的患者组成。两组患者的 PHPT 持续时间相当:mPHPT - 1 年 [0; 3] 与 sPHPT - 1 年 [0; 1],(P=0.533,U 检验)。钙磷代谢的主要参数以及肾脏并发症的发生率均无差异。在 mPHPT 组中,骨异常的发生率明显高于 sPHPT 组:54 对 10%(p=<0.001;F 检验)。mPHPT 组的股骨颈和全髋的 BMD 和 Z 评分值均低于 mPHPT 组,这在统计学上有显著差异。在将亚组 1A 与 sPHPT 进行比较时,这些差异仍然明显:结论:与 sPHPT 相比,与 MEN1 相关的 PHPT 可能伴有更严重的股骨颈和全髋骨 BMD 下降,与其他激素分泌 NEN 无关。澄清 MEN1 基因突变在这些过程中的作用还需要进一步研究。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信